<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">oncotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский онкологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian journal of oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1814-4861</issn><issn pub-type="epub">2312-3168</issn><publisher><publisher-name>Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21294/1814-4861-2023-22-6-138-152</article-id><article-id custom-type="elpub" pub-id-type="custom">oncotomsk-2844</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Влияние молекулярно-генетического профиля менингиом на течение заболевания и рецидивирование при использовании комбинированного метода лечения</article-title><trans-title-group xml:lang="en"><trans-title>Impact of molecular genetic profle of meningiomas on the clinical course and recurrence using combined modality treatment</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3558-810X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сергеев</surname><given-names>Г. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Sergeev</surname><given-names>G. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сергеев Глеб Сергеевич - кандидат медицинских наук, нейрохирург, </p><p>129090, г. Москва, ул. Щепкина, 35</p></bio><bio xml:lang="en"><p>Gleb S. Sergeev - MD, PhD, Neurosurgeon, Neurosurgery Clinic, </p><p>35, Shchepkina St., Moscow, 129090</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1003-0292</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гайтан</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Gaytan</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гайтан Алексей Сергеевич - кандидат медицинских наук, нейрохирург, 129090, г. Москва, ул. Щепкина, 35;</p><p>доцент кафедры неврологии и нейрохирургии с курсом комплексной реабилитации, 117198, г. Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>Alexey S. Gaytan - MD, PhD, Neurosurgeon, 35, Shchepkina St., Moscow, 129090;</p><p>Associate Professor of the Department of Neurology and Neurosurgery with a course of comprehensive rehabilitation, 6, Miklukho-Maklaya St., Moscow, 117198</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6385-5784</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Травин</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Travin</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Травин Михаил Андреевич - кандидат медицинских наук, руководитель патоморфологической лаборатории, </p><p>129090, г. Москва, ул. Щепкина, 35</p></bio><bio xml:lang="en"><p>Mikhail A. Travin - MD, PhD, Head of the Pathomorphological Laboratory, </p><p>35, Shchepkina St., Moscow, 129090</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4242-5723</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пономарев</surname><given-names>А. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Ponomarev</surname><given-names>A. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пономарев Андрей Борисович - кандидат медицинских наук, доцент Института клинической морфологии и цифровой патологии, </p><p>119991, г. Москва, ул. Трубецкая, 8/2</p></bio><bio xml:lang="en"><p>Andrey B. Ponomarev - MD, PhD, Associate Professor at the Institute of Clinical Morphology and Digital Pathology, </p><p>8/2, Trubetskaya St., Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8473-3161</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Афонина</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Afonina</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Афонина Мария Алексеевна - ассистент института клинической морфологии и цифровой патологии, </p><p>119991, г. Москва, ул. Трубецкая, 8/2</p></bio><bio xml:lang="en"><p>Maria A. Afonina - Assistant at the Institute of Clinical Morphology and Digital Pathology,</p><p>8/2, Trubetskaya St., Moscow, 119991</p></bio><email xlink:type="simple">afoninama2497@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5823-9434</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савицкая</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Savitskaya</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Савицкая Ирина Андреевна - кандидат медицинских наук, рентгенолог отделения лучевой диагностики, </p><p>129090, г. Москва, ул. Щепкина, 35</p></bio><bio xml:lang="en"><p>Irina A. Savitskaya - MD, PhD, Radiologist, Radiology Department, </p><p>35, Shchepkina St., Moscow, 129090</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-9035-8888</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яхья</surname><given-names>Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakhya</surname><given-names>F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Яхья Фатима - ординатор кафедры неврологии и нейрохирургии с курсом комплексной реабилитации, </p><p>117198, г. Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>Fatima Yakhya - Resident of the Department of Neurology and Neurosurgery with a course of comprehensive rehabilitation,</p><p>6, Miklukho-Maklaya St., Moscow, 117198</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0789-8039</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кривошапкин</surname><given-names>А. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Krivoshapkin</surname><given-names>A. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кривошапкин Алексей Леонидович - доктор медицинских наук, профессор, член-корреспондент РАН, заведующий клиникой нейрохирургии, 129090, г. Москва, ул. Щепкина, 35;</p><p>заведующий кафедрой неврологии и нейрохирургии с курсом комплексной реабилитации, 117198, г. Москва, ул. Миклухо-Маклая, 6;</p><p>главный научный сотрудник, 630055, г. Новосибирск, ул. Речкуновская, 15</p></bio><bio xml:lang="en"><p>Alexey L. Krivoshapkin - MD, Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Neurosurgery, 35, Shchepkina St., Moscow, 129090;</p><p>Head of the Department of Neurology and Neurosurgery with a course of comprehensive rehabilitation, 6, Miklukho-Maklaya St., Moscow, 117198;</p><p>Chief Researcher, 15, Rechkunovskaya St., Novosibirsk, 630055</p></bio><xref ref-type="aff" rid="aff-5"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Клиника нейрохирургии, Европейский Медицинский Центр</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Neurosurgery Clinic, European Medical Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Клиника нейрохирургии, Европейский Медицинский Центр;&#13;
ФГАОУ ВО «Российский университет дружбы народов»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Neurosurgery Clinic, European Medical Center;&#13;
RUDN University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский университет дружбы народов»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>RUDN University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>Клиника нейрохирургии, Европейский Медицинский Центр;&#13;
ФГАОУ ВО «Российский университет дружбы народов»;&#13;
ФГБУ «Национальный медицинский исследовательский центр им. акад. Е.Н. Мешалкина» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Neurosurgery Clinic, European Medical Center;&#13;
RUDN University;&#13;
E.N. Meshalkin National Medical Research Center of the Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>03</day><month>01</month><year>2024</year></pub-date><volume>22</volume><issue>6</issue><fpage>138</fpage><lpage>152</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сергеев Г.С., Гайтан А.С., Травин М.А., Пономарев А.Б., Афонина М.А., Савицкая И.А., Яхья Ф., Кривошапкин А.Л., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Сергеев Г.С., Гайтан А.С., Травин М.А., Пономарев А.Б., Афонина М.А., Савицкая И.А., Яхья Ф., Кривошапкин А.Л.</copyright-holder><copyright-holder xml:lang="en">Sergeev G.S., Gaytan A.S., Travin M.A., Ponomarev A.B., Afonina M.A., Savitskaya I.A., Yakhya F., Krivoshapkin A.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.siboncoj.ru/jour/article/view/2844">https://www.siboncoj.ru/jour/article/view/2844</self-uri><abstract><sec><title>Введение</title><p>Введение. Менингиома, одна из самых распространенных опухолей центральной нервной системы, составляет 39,7 % всех выявляемых первичных опухолей головного мозга. Источником возникновения этих новообразований являются менинготелиальные клетки паутинной оболочки. Менингиомы отличаются широким спектром гистологических вариантов, что выражается в наличии 15 гистоподтипов. Гистологическая классификация менингиом позволяет предположить дальнейшее развитие заболевания, спрогнозировать риски рецидива опухоли, определить тактику ведения пациента. Однако клинические исходы в гистологических подгруппах пациентов часто противоречат гистологической градации злокачественности. Таким образом, необходим более надежный метод как для определения гистологического подтипа опухоли, так и для прогнозирования клинического течения заболевания с потенциалом для таргетного лечения.</p><p>Цель исследования – обобщить литературные данные о влиянии результата геномного и протеомного анализа опухоли на канцерогенез с определением взаимосвязи данных мутационных изменений с неинвазивной диагностикой, лечением и течением заболевания.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Поиск литературы производился в системе PubMed, Elibrary, включались публикации преимущественно с 2010 по 2023 г. с идентификацией статей по ключевому слову «генетический анализ менингиом» и синонимами. Найдено 550 источников, из которых 55 использовано для написания литературного обзора. Ряд статей, опубликованных ранее 2010 г., использованы для исторической справки о методах лечения и диагностики. Данные статьи не включали информацию о генетическом аспекте публикации.</p></sec><sec><title>Заключение</title><p>Заключение. Продолжение изучения молекулярно-генетического профиля менингиом, в том числе, возможно, измененного под воздействием комплексного лечения, позволит усовершенствовать классификацию и определить корреляционную зависимость между морфологическим, молекулярно-генетическим профилем опухоли, структурой менингиомы на основе анализа данных МРТ и клиническим течением заболевания.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Meningioma is one of the most common central nervous system tumors, accounting for 39.7 % of all primary brain tumors. The tumor originates from arachnoid meningothelial cells and is characterized by a wide range of histological types classified into 15 subtypes. The histological classification of meningiomas allows us to predict meningioma behavior and the risk of disease recurrence, as well as to define treatment strategies. However, clinical outcomes in histological subgroups of patients are often inconsistent with the histological grade of malignancy. Thus, a more reliable method is needed both to determine the histological subtype of the tumor and to predict the clinical course of the disease with the potential for targeted treatment.</p><p>The purpose of the study was to summarize the available data on the effect of results of the genomic and proteomic tumor analysis on carcinogenesis with the relationship between the mutational changes and noninvasive diagnosis, treatment and the course of the disease.</p></sec><sec><title>Material and Methods</title><p>Material and Methods. Literature search was carried out in the PubMed, Elibrary system, publications were included mainly from 2010 to 2023. with the identification of articles by the keyword “genetic analysis of meningiomas” and synonyms. 550 articles were found, of which 55 were used to write a literature review.</p></sec><sec><title>Conclusion</title><p>Conclusion. The study of the molecular genetic profile of meningiomas will improve the classification and establish a correlation with MRI data, the course of the disease and prognosis.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>менингиома</kwd><kwd>геномный и протеомный анализ</kwd><kwd>мезенхимальные опухоли ЦНС</kwd><kwd>комплексное лечение менингиом</kwd><kwd>терапевтические мишени</kwd></kwd-group><kwd-group xml:lang="en"><kwd>meningioma</kwd><kwd>genomic and proteomic analysis</kwd><kwd>mesenchymal tumors of the CNS</kwd><kwd>targeted treatment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ostrom Q.T., Price M., Neff C., Cioff G., Waite K.A., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019. Neuro Oncol. 2022; 24(s5): 1–95. doi: 10.1093/neuonc/noac202.</mixed-citation><mixed-citation xml:lang="en">Ostrom Q.T., Price M., Neff C., Cioff G., Waite K.A., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019. Neuro Oncol. 2022; 24(s5): 1–95. doi: 10.1093/neuonc/noac202.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Pearson B.E., Markert J.M., Fisher W.S., Guthrie B.L., Fiveash J.B., Palmer C.A., Riley K. Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus. 2008; 24(5). doi: 10.3171/FOC/2008/24/5/E3.</mixed-citation><mixed-citation xml:lang="en">Pearson B.E., Markert J.M., Fisher W.S., Guthrie B.L., Fiveash J.B., Palmer C.A., Riley K. Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus. 2008; 24(5). doi: 10.3171/FOC/2008/24/5/E3.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hsu D.W., Efrd J.T., Hedley-Whyte E.T. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg. 1997; 86(1): 113–20. doi: 10.3171/jns.1997.86.1.0113.</mixed-citation><mixed-citation xml:lang="en">Hsu D.W., Efrd J.T., Hedley-Whyte E.T. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg. 1997; 86(1): 113–20. doi: 10.3171/jns.1997.86.1.0113.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ribalta T., McCutcheon I.E., Aldape K.D., Bruner J.M., Fuller G.N. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol. 2004; 28(11): 1532–6. doi: 10.1097/01.pas.0000141389.06925.d5.</mixed-citation><mixed-citation xml:lang="en">Ribalta T., McCutcheon I.E., Aldape K.D., Bruner J.M., Fuller G.N. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol. 2004; 28(11): 1532–6. doi: 10.1097/01.pas.0000141389.06925.d5.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Artlich A., Schmidt D. Immunohistochemical profle of meningiomas and their histological subtypes. Hum Pathol. 1990; 21(8): 843–9. doi: 10.1016/0046-8177(90)90054-9.</mixed-citation><mixed-citation xml:lang="en">Artlich A., Schmidt D. Immunohistochemical profle of meningiomas and their histological subtypes. Hum Pathol. 1990; 21(8): 843–9. doi: 10.1016/0046-8177(90)90054-9.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Schnitt S.J., Vogel H. Meningiomas. Diagnostic value of immunoperoxidase staining for epithelial membrane antigen. Am J Surg Pathol. 1986; 10(9): 640–9. doi: 10.1097/00000478-198609000-00006.</mixed-citation><mixed-citation xml:lang="en">Schnitt S.J., Vogel H. Meningiomas. Diagnostic value of immunoperoxidase staining for epithelial membrane antigen. Am J Surg Pathol. 1986; 10(9): 640–9. doi: 10.1097/00000478-198609000-00006.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kalamarides M., Niwa-Kawakita M., Leblois H., Abramowski V., Perricaudet M., Janin A., Thomas G., Gutmann D.H., Giovannini M. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev. 2002; 16(9): 1060–5. doi: 10.1101/gad.226302.</mixed-citation><mixed-citation xml:lang="en">Kalamarides M., Niwa-Kawakita M., Leblois H., Abramowski V., Perricaudet M., Janin A., Thomas G., Gutmann D.H., Giovannini M. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev. 2002; 16(9): 1060–5. doi: 10.1101/gad.226302.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Abedalthagaf M.S., Merrill P.H., Bi W.L., Jones R.T., Listewnik M.L., Ramkissoon S.H., Thorner A.R., Dunn I.F., Beroukhim R., Alexander B.M., Brastianos P.K., Francis J.M., Folkerth R.D., Ligon K.L., Van Hummelen P., Ligon A.H., Santagata S. Angiomatous meningiomas have a distinct genetic profle with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget. 2014; 5(21): 10596–606. doi: 10.18632/oncotarget.2517.</mixed-citation><mixed-citation xml:lang="en">Abedalthagaf M.S., Merrill P.H., Bi W.L., Jones R.T., Listewnik M.L., Ramkissoon S.H., Thorner A.R., Dunn I.F., Beroukhim R., Alexander B.M., Brastianos P.K., Francis J.M., Folkerth R.D., Ligon K.L., Van Hummelen P., Ligon A.H., Santagata S. Angiomatous meningiomas have a distinct genetic profle with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget. 2014; 5(21): 10596–606. doi: 10.18632/oncotarget.2517.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bi W.L., Abedalthagaf M., Horowitz P., Agarwalla P.K., Mei Y., Aizer A.A., Brewster R., Dunn G.P., Al-Mefty O., Alexander B.M., Santagata S., Beroukhim R., Dunn I.F. Genomic landscape of intracranial meningiomas. J Neurosurg. 2016; 125(3): 525–35. doi: 10.3171/2015.6.JNS15591.</mixed-citation><mixed-citation xml:lang="en">Bi W.L., Abedalthagaf M., Horowitz P., Agarwalla P.K., Mei Y., Aizer A.A., Brewster R., Dunn G.P., Al-Mefty O., Alexander B.M., Santagata S., Beroukhim R., Dunn I.F. Genomic landscape of intracranial meningiomas. J Neurosurg. 2016; 125(3): 525–35. doi: 10.3171/2015.6.JNS15591.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Abedalthagaf M., Bi W.L., Aizer A.A., Merrill P.H., Brewster R., Agarwalla P.K., Listewnik M.L., Dias-Santagata D., Thorner A.R., van Hummelen P., Brastianos P.K., Reardon D.A., Wen P.Y., Al-Mefty O., Ramkissoon S.H., Folkerth R.D., Ligon K.L., Ligon A.H., Alexander B.M., Dunn I.F., Beroukhim R., Santagata S. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016; 18(5): 649–55. doi: 10.1093/neuonc/nov316.</mixed-citation><mixed-citation xml:lang="en">Abedalthagaf M., Bi W.L., Aizer A.A., Merrill P.H., Brewster R., Agarwalla P.K., Listewnik M.L., Dias-Santagata D., Thorner A.R., van Hummelen P., Brastianos P.K., Reardon D.A., Wen P.Y., Al-Mefty O., Ramkissoon S.H., Folkerth R.D., Ligon K.L., Ligon A.H., Alexander B.M., Dunn I.F., Beroukhim R., Santagata S. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016; 18(5): 649–55. doi: 10.1093/neuonc/nov316.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Choy W., Kim W., Nagasawa D., Stramotas S., Yew A., Gopen Q., Parsa A.T., Yang I. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus. 2011; 30(5). doi: 10.3171/2011.2.FOCUS1116.</mixed-citation><mixed-citation xml:lang="en">Choy W., Kim W., Nagasawa D., Stramotas S., Yew A., Gopen Q., Parsa A.T., Yang I. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus. 2011; 30(5). doi: 10.3171/2011.2.FOCUS1116.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Collord G., Tarpey P., Kurbatova N., Martincorena I., Moran S., Castro M., Nagy T., Bignell G., Maura F., Young M.D., Berna J., Tubio J.M.C., McMurran C.E., Young A.M.H., Sanders M., Noorani I., Price S.J., Watts C., Leipnitz E., Kirsch M., Schackert G., Pearson D., Devadass A., Ram Z., Collins V.P., Allinson K., Jenkinson M.D., Zakaria R., Syed K., Hanemann C.O., Dunn J., McDermott M.W., Kirollos R.W., Vassiliou G.S., Esteller M., Behjati S., Brazma A., Santarius T., McDermott U. An integrated genomic analysis of anaplastic meningioma identifes prognostic molecular signatures. Sci Rep. 2018; 8(1). doi: 10.1038/s41598-018-31659-0.</mixed-citation><mixed-citation xml:lang="en">Collord G., Tarpey P., Kurbatova N., Martincorena I., Moran S., Castro M., Nagy T., Bignell G., Maura F., Young M.D., Berna J., Tubio J.M.C., McMurran C.E., Young A.M.H., Sanders M., Noorani I., Price S.J., Watts C., Leipnitz E., Kirsch M., Schackert G., Pearson D., Devadass A., Ram Z., Collins V.P., Allinson K., Jenkinson M.D., Zakaria R., Syed K., Hanemann C.O., Dunn J., McDermott M.W., Kirollos R.W., Vassiliou G.S., Esteller M., Behjati S., Brazma A., Santarius T., McDermott U. An integrated genomic analysis of anaplastic meningioma identifes prognostic molecular signatures. Sci Rep. 2018; 8(1). doi: 10.1038/s41598-018-31659-0.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Sievers P., Sill M., Blume C., Tauziede-Espariat A., Schrimpf D., Stichel D., Reuss D.E., Dogan H., Hartmann C., Mawrin C., Hasselblatt M., Stummer W., Schick U., Hench J., Frank S., Ketter R., Schweizer L., Schittenhelm J., Puget S., Brandner S., Jaunmuktane Z., Küsters B., Abdullaev Z., Pekmezci M., Snuderl M., Ratliff M., Herold-Mende C., Unterberg A., Aldape K., Ellison D.W., Wesseling P., Reifenberger G., Wick W., Perry A., Varlet P., Pfster S.M., Jones D.T.W., von Deimling A., Sahm F.; German Consortium “Aggressive Meningiomas”. Clear cell meningiomas are defned by a highly distinct DNA methylation profle and mutations in SMARCE1. Acta Neuropathol. 2021; 141(2): 281–90. doi: 10.1007/s00401-020-02247-2.</mixed-citation><mixed-citation xml:lang="en">Sievers P., Sill M., Blume C., Tauziede-Espariat A., Schrimpf D., Stichel D., Reuss D.E., Dogan H., Hartmann C., Mawrin C., Hasselblatt M., Stummer W., Schick U., Hench J., Frank S., Ketter R., Schweizer L., Schittenhelm J., Puget S., Brandner S., Jaunmuktane Z., Küsters B., Abdullaev Z., Pekmezci M., Snuderl M., Ratliff M., Herold-Mende C., Unterberg A., Aldape K., Ellison D.W., Wesseling P., Reifenberger G., Wick W., Perry A., Varlet P., Pfster S.M., Jones D.T.W., von Deimling A., Sahm F.; German Consortium “Aggressive Meningiomas”. Clear cell meningiomas are defned by a highly distinct DNA methylation profle and mutations in SMARCE1. Acta Neuropathol. 2021; 141(2): 281–90. doi: 10.1007/s00401-020-02247-2.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Schmidt M., Mock A., Jungk C., Sahm F., Ull A.T., Warta R., Lamszus K., Gousias K., Ketter R., Roesch S., Rapp C., Schefzyk S., Urbschat S., Lahrmann B., Kessler A.F., Löhr M., Senft C., Grabe N., Reuss D., Beckhove P., Westphal M., von Deimling A., Unterberg A., Simon M., Herold-Mende C. Transcriptomic analysis of aggressive meningiomas identifes PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. Oncotarget. 2016; 7(12): 14551–68. doi: 10.18632/oncotarget.7396.</mixed-citation><mixed-citation xml:lang="en">Schmidt M., Mock A., Jungk C., Sahm F., Ull A.T., Warta R., Lamszus K., Gousias K., Ketter R., Roesch S., Rapp C., Schefzyk S., Urbschat S., Lahrmann B., Kessler A.F., Löhr M., Senft C., Grabe N., Reuss D., Beckhove P., Westphal M., von Deimling A., Unterberg A., Simon M., Herold-Mende C. Transcriptomic analysis of aggressive meningiomas identifes PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. Oncotarget. 2016; 7(12): 14551–68. doi: 10.18632/oncotarget.7396.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sahm F., Schrimpf D., Stichel D., Jones D.T.W., Hielscher T., Schefzyk S., Okonechnikov K., Koelsche C., Reuss D.E., Capper D., Sturm D., Wirsching H.G., Berghoff A.S., Baumgarten P., Kratz A., Huang K., Wefers A.K., Hovestadt V., Sill M., Ellis H.P., Kurian K.M., Okuducu A.F., Jungk C., Drueschler K., Schick M., Bewerunge-Hudler M., Mawrin C., Seiz-Rosenhagen M., Ketter R., Simon M., Westphal M., Lamszus K., Becker A., Koch A., Schittenhelm J., Rushing E.J., Collins V.P., Brehmer S., Chavez L., Platten M., Hänggi D., Unterberg A., Paulus W., Wick W., Pfster S.M., Mittelbronn M., Preusser M., Herold-Mende C., Weller M., von Deimling A. DNA methylation-based classifcation and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017; 18(5): 682–94. doi: 10.1016/S1470-2045(17)30155-9.</mixed-citation><mixed-citation xml:lang="en">Sahm F., Schrimpf D., Stichel D., Jones D.T.W., Hielscher T., Schefzyk S., Okonechnikov K., Koelsche C., Reuss D.E., Capper D., Sturm D., Wirsching H.G., Berghoff A.S., Baumgarten P., Kratz A., Huang K., Wefers A.K., Hovestadt V., Sill M., Ellis H.P., Kurian K.M., Okuducu A.F., Jungk C., Drueschler K., Schick M., Bewerunge-Hudler M., Mawrin C., Seiz-Rosenhagen M., Ketter R., Simon M., Westphal M., Lamszus K., Becker A., Koch A., Schittenhelm J., Rushing E.J., Collins V.P., Brehmer S., Chavez L., Platten M., Hänggi D., Unterberg A., Paulus W., Wick W., Pfster S.M., Mittelbronn M., Preusser M., Herold-Mende C., Weller M., von Deimling A. DNA methylation-based classifcation and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017; 18(5): 682–94. doi: 10.1016/S1470-2045(17)30155-9.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Dunn J., Ferluga S., Sharma V., Futschik M., Hilton D.A., Adams C.L., Lasonder E., Hanemann C.O. Proteomic analysis discovers the diferential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism. EBioMedicine. 2019; 40: 77–91. doi: 10.1016/j.ebiom.2018.12.048.</mixed-citation><mixed-citation xml:lang="en">Dunn J., Ferluga S., Sharma V., Futschik M., Hilton D.A., Adams C.L., Lasonder E., Hanemann C.O. Proteomic analysis discovers the diferential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism. EBioMedicine. 2019; 40: 77–91. doi: 10.1016/j.ebiom.2018.12.048.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Parada C.A., Osbun J., Kaur S., Yakkioui Y., Shi M., Pan C., Busald T., Karasozen Y., Gonzalez-Cuyar L.F., Rostomily R., Zhang J., Ferreira M. Kinome and phosphoproteome of high-grade meningiomas reveal AKAP12 as a central regulator of aggressiveness and its possible role in progression. Sci Rep. 2018; 8(1): 2098. doi: 10.1038/s41598-018-19308-y.</mixed-citation><mixed-citation xml:lang="en">Parada C.A., Osbun J., Kaur S., Yakkioui Y., Shi M., Pan C., Busald T., Karasozen Y., Gonzalez-Cuyar L.F., Rostomily R., Zhang J., Ferreira M. Kinome and phosphoproteome of high-grade meningiomas reveal AKAP12 as a central regulator of aggressiveness and its possible role in progression. Sci Rep. 2018; 8(1): 2098. doi: 10.1038/s41598-018-19308-y.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Cui G.Q., Jiao A.H., Xiu C.M., Wang Y.B., Sun P., Zhang L.M., Li X.G. Proteomic analysis of meningiomas. Acta Neurol Belg. 2014; 114(3): 187–94. doi: 10.1007/s13760-013-0253-z.</mixed-citation><mixed-citation xml:lang="en">Cui G.Q., Jiao A.H., Xiu C.M., Wang Y.B., Sun P., Zhang L.M., Li X.G. Proteomic analysis of meningiomas. Acta Neurol Belg. 2014; 114(3): 187–94. doi: 10.1007/s13760-013-0253-z.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Dumic J., Dabelic S., Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006; 1760(4): 616–35. doi: 10.1016/j.bbagen.2005.12.020.</mixed-citation><mixed-citation xml:lang="en">Dumic J., Dabelic S., Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006; 1760(4): 616–35. doi: 10.1016/j.bbagen.2005.12.020.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Wibom C., Mörén L., Aarhus M., Knappskog P.M., Lund-Johansen M., Antti H., Bergenheim A.T. Proteomic profles difer between bone invasive and noninvasive benign meningiomas of fbrous and meningothelial subtype. J Neurooncol. 2009; 94(3): 321–31. doi: 10.1007/s11060-009-9865-9.</mixed-citation><mixed-citation xml:lang="en">Wibom C., Mörén L., Aarhus M., Knappskog P.M., Lund-Johansen M., Antti H., Bergenheim A.T. Proteomic profles difer between bone invasive and noninvasive benign meningiomas of fbrous and meningothelial subtype. J Neurooncol. 2009; 94(3): 321–31. doi: 10.1007/s11060-009-9865-9.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Okamoto H., Li J., Vortmeyer A.O., Jaffe H., Lee Y.S., Gläsker S., Sohn T.S., Zeng W., Ikejiri B., Proescholdt M.A., Mayer C., Weil R.J., Oldfeld E.H., Zhuang Z. Comparative proteomic profles of meningioma subtypes. Cancer Res. 2006; 66(20): 10199–204. doi: 10.1158/0008-5472.CAN-06-0955.</mixed-citation><mixed-citation xml:lang="en">Okamoto H., Li J., Vortmeyer A.O., Jaffe H., Lee Y.S., Gläsker S., Sohn T.S., Zeng W., Ikejiri B., Proescholdt M.A., Mayer C., Weil R.J., Oldfeld E.H., Zhuang Z. Comparative proteomic profles of meningioma subtypes. Cancer Res. 2006; 66(20): 10199–204. doi: 10.1158/0008-5472.CAN-06-0955.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Dunn J., Lenis V.P., Hilton D.A., Warta R., Herold-Mende C., Hanemann C.O., Futschik M.E. Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma. Cancers (Basel). 2020; 12(11): 3270. doi: 10.3390/cancers12113270.</mixed-citation><mixed-citation xml:lang="en">Dunn J., Lenis V.P., Hilton D.A., Warta R., Herold-Mende C., Hanemann C.O., Futschik M.E. Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma. Cancers (Basel). 2020; 12(11): 3270. doi: 10.3390/cancers12113270.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Louis D.N., Perry A., Wesseling P., Brat D.J., Cree I.A., Figarella-Branger D., Hawkins C., Ng H.K., Pfster S.M., Reifenberger G., Soffetti R., von Deimling A., Ellison D.W. The 2021 WHO Classifcation of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8): 1231–51. doi: 10.1093/neuonc/noab106.</mixed-citation><mixed-citation xml:lang="en">Louis D.N., Perry A., Wesseling P., Brat D.J., Cree I.A., Figarella-Branger D., Hawkins C., Ng H.K., Pfster S.M., Reifenberger G., Soffetti R., von Deimling A., Ellison D.W. The 2021 WHO Classifcation of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8): 1231–51. doi: 10.1093/neuonc/noab106.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Bendszus M., Martin-Schrader I., Warmuth-Metz M., Hofmann E., Solymosi L. MR imaging- and MR spectroscopy-revealed changes in meningiomas for which embolization was performed without subsequent surgery. Am J Neuroradiol. 2000; 21(4): 666–9.</mixed-citation><mixed-citation xml:lang="en">Bendszus M., Martin-Schrader I., Warmuth-Metz M., Hofmann E., Solymosi L. MR imaging- and MR spectroscopy-revealed changes in meningiomas for which embolization was performed without subsequent surgery. Am J Neuroradiol. 2000; 21(4): 666–9.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Romani R., Tang W.J., Mao Y., Wang D.J., Tang H.L., Zhu F.P., Che X.M., Gong Y., Zheng K., Zhong P., Li S.Q., Bao W.M., Benner C., Wu J.S., Zhou L.F. Difusion tensor magnetic resonance imaging for predicting the consistency of intracranial meningiomas. Acta Neurochir (Wien). 2014; 156(10): 1837–45. doi: 10.1007/s00701-014-2149-y.</mixed-citation><mixed-citation xml:lang="en">Romani R., Tang W.J., Mao Y., Wang D.J., Tang H.L., Zhu F.P., Che X.M., Gong Y., Zheng K., Zhong P., Li S.Q., Bao W.M., Benner C., Wu J.S., Zhou L.F. Difusion tensor magnetic resonance imaging for predicting the consistency of intracranial meningiomas. Acta Neurochir (Wien). 2014; 156(10): 1837–45. doi: 10.1007/s00701-014-2149-y.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kashimura H., Inoue T., Ogasawara K., Arai H., Otawara Y., Kanbara Y., Ogawa A. Prediction of meningioma consistency using fractional anisotropy value measured by magnetic resonance imaging. J Neurosurg. 2007; 107(4): 784–7. doi: 10.3171/JNS-07/10/0784.</mixed-citation><mixed-citation xml:lang="en">Kashimura H., Inoue T., Ogasawara K., Arai H., Otawara Y., Kanbara Y., Ogawa A. Prediction of meningioma consistency using fractional anisotropy value measured by magnetic resonance imaging. J Neurosurg. 2007; 107(4): 784–7. doi: 10.3171/JNS-07/10/0784.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Sitthinamsuwan B., Khampalikit I., Nunta-aree S., Srirabheebhat P., Witthiwej T., Nitising A. Predictors of meningioma consistency: A study in 243 consecutive cases. Acta Neurochir (Wien). 2012; 154: 1383–9. doi: 10.1007/s00701-012-1427-9.</mixed-citation><mixed-citation xml:lang="en">Sitthinamsuwan B., Khampalikit I., Nunta-aree S., Srirabheebhat P., Witthiwej T., Nitising A. Predictors of meningioma consistency: A study in 243 consecutive cases. Acta Neurochir (Wien). 2012; 154: 1383–9. doi: 10.1007/s00701-012-1427-9.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Lee J.G., Song S.W., Koh Y.C., Cho J., Choi J.W., Roh H.G., Lim S.D. Primary intracranial fbrosarcoma presenting with hemorrhage. Brain Tumor Res Treat. 2013; 1(2): 9–4. doi: 10.14791/btrt.2013.1.2.91.</mixed-citation><mixed-citation xml:lang="en">Lee J.G., Song S.W., Koh Y.C., Cho J., Choi J.W., Roh H.G., Lim S.D. Primary intracranial fbrosarcoma presenting with hemorrhage. Brain Tumor Res Treat. 2013; 1(2): 9–4. doi: 10.14791/btrt.2013.1.2.91.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Liu G., Chen Z.Y., Ma L., Lou X., Li S.J., Wang Y.L. Intracranial hemangiopericytoma: MR imaging fndings and diagnostic usefulness of minimum ADC values. J Magn Reson Imaging. 2013; 38(5): 1146–51. doi: 10.1002/jmri.24075.</mixed-citation><mixed-citation xml:lang="en">Liu G., Chen Z.Y., Ma L., Lou X., Li S.J., Wang Y.L. Intracranial hemangiopericytoma: MR imaging fndings and diagnostic usefulness of minimum ADC values. J Magn Reson Imaging. 2013; 38(5): 1146–51. doi: 10.1002/jmri.24075.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Ma C., Xu F., Xiao Y.D., Paudel R., Sun Y., Xiao E.H. Magnetic resonance imaging of intracranial hemangiopericytoma and correlation with pathological fndings. Oncol Lett. 2014; 8: 2140–4. doi: 10.3892/ol.2014.2503.</mixed-citation><mixed-citation xml:lang="en">Ma C., Xu F., Xiao Y.D., Paudel R., Sun Y., Xiao E.H. Magnetic resonance imaging of intracranial hemangiopericytoma and correlation with pathological fndings. Oncol Lett. 2014; 8: 2140–4. doi: 10.3892/ol.2014.2503.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Murphy M.C., Huston J., Glaser K.J., Manduca A., Meyer F.B., Lanzino G., Morris J.M., Felmlee J.P., Ehman R.L. Preoperative assessment of meningioma stifness using magnetic resonance elastography. J Neurosurg. 2013; 118(3): 643–8. doi: 10.3171/2012.9.JNS12519.</mixed-citation><mixed-citation xml:lang="en">Murphy M.C., Huston J., Glaser K.J., Manduca A., Meyer F.B., Lanzino G., Morris J.M., Felmlee J.P., Ehman R.L. Preoperative assessment of meningioma stifness using magnetic resonance elastography. J Neurosurg. 2013; 118(3): 643–8. doi: 10.3171/2012.9.JNS12519.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Krivoshapkin A.L., Sergeev G.S., Kalneus L.E., Gaytan A.S., Murtazin V.I., Kurbatov V.P., Volkov A.M., Kostromskaya D.V., Pyatov S.M., Amelin M.E., Duishobaev A.R. New Software for Preoperative Diagnostics of Meningeal Tumor Histologic Types. World Neurosurg. 2016; 90: 123–32. doi: 10.1016/j.wneu.2016.02.084.</mixed-citation><mixed-citation xml:lang="en">Krivoshapkin A.L., Sergeev G.S., Kalneus L.E., Gaytan A.S., Murtazin V.I., Kurbatov V.P., Volkov A.M., Kostromskaya D.V., Pyatov S.M., Amelin M.E., Duishobaev A.R. New Software for Preoperative Diagnostics of Meningeal Tumor Histologic Types. World Neurosurg. 2016; 90: 123–32. doi: 10.1016/j.wneu.2016.02.084.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Braunstein J.B., Vick N.A. Meningiomas: the decision not to operate. Neurology. 1997; 48(5): 1459–62. doi: 10.1212/wnl.48.5.1459.</mixed-citation><mixed-citation xml:lang="en">Braunstein J.B., Vick N.A. Meningiomas: the decision not to operate. Neurology. 1997; 48(5): 1459–62. doi: 10.1212/wnl.48.5.1459.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Akeyson E.W., McCutcheon I.E. Management of benign and aggressive intracranial meningiomas. Oncology (Huntington) 1996; 10(5): 747–56.</mixed-citation><mixed-citation xml:lang="en">Akeyson E.W., McCutcheon I.E. Management of benign and aggressive intracranial meningiomas. Oncology (Huntington) 1996; 10(5): 747–56.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Chamberlain M.C. Intracerebral Meningiomas. Curr Treat Options Neurol. 2004; 6(4): 297–305. doi: 10.1007/s11940-004-0029-0.</mixed-citation><mixed-citation xml:lang="en">Chamberlain M.C. Intracerebral Meningiomas. Curr Treat Options Neurol. 2004; 6(4): 297–305. doi: 10.1007/s11940-004-0029-0.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Goldsmith B.J., Wara W.M., Wilson C.B., Larson D.A. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg. 1994; 80(2): 195–201. doi: 10.3171/jns.1994.80.2.0195.</mixed-citation><mixed-citation xml:lang="en">Goldsmith B.J., Wara W.M., Wilson C.B., Larson D.A. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg. 1994; 80(2): 195–201. doi: 10.3171/jns.1994.80.2.0195.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Wilson C.B. Meningiomas: genetics, malignancy, and the role of radiation in induction and treatment. The Richard C. Schneider Lecture. J Neurosurg. 1994; 81(5): 666–75. doi: 10.3171/jns.1994.81.5.0666.</mixed-citation><mixed-citation xml:lang="en">Wilson C.B. Meningiomas: genetics, malignancy, and the role of radiation in induction and treatment. The Richard C. Schneider Lecture. J Neurosurg. 1994; 81(5): 666–75. doi: 10.3171/jns.1994.81.5.0666.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Kokubo M., Shibamoto Y., Takahashi J.A., Sasai K., Oya N., Hashimoto N., Hiraoka M. Efcacy of conventional radiotherapy for recurrent meningioma. J Neurooncol. 2000; 48(1): 51–5. doi: 10.1023/a:1006430102406.</mixed-citation><mixed-citation xml:lang="en">Kokubo M., Shibamoto Y., Takahashi J.A., Sasai K., Oya N., Hashimoto N., Hiraoka M. Efcacy of conventional radiotherapy for recurrent meningioma. J Neurooncol. 2000; 48(1): 51–5. doi: 10.1023/a:1006430102406.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Jääskeläinen J., Haltia M., Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol. 1986; 25(3): 233–42. doi: 10.1016/0090-3019(86)90233-8.</mixed-citation><mixed-citation xml:lang="en">Jääskeläinen J., Haltia M., Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol. 1986; 25(3): 233–42. doi: 10.1016/0090-3019(86)90233-8.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Hug E.B., Devries A., Thornton A.F., Munzenride J.E., Pardo F.S., Hedley-Whyte E.T., Bussiere M.R., Ojemann R. Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy. J Neurooncol. 2000; 48(2): 151–60. doi: 10.1023/a:1006434124794.</mixed-citation><mixed-citation xml:lang="en">Hug E.B., Devries A., Thornton A.F., Munzenride J.E., Pardo F.S., Hedley-Whyte E.T., Bussiere M.R., Ojemann R. Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy. J Neurooncol. 2000; 48(2): 151–60. doi: 10.1023/a:1006434124794.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Horbinski C., Nabors L.B., Portnow J., Baehring J., Bhatia A., Bloch O., Brem S., Butowski N., Cannon D.M., Chao S., Chheda M.G., Fabiano A.J., Forsyth P., Gigilio P., Hattangadi-Gluth J., Holdhoff M., Junck L., Kaley T., Merrell R., Mrugala M.M., Nagpal S., Nedzi L.A., Nevel K., Nghiemphu P.L., Parney I., Patel T.R., Peters K., Puduvalli V.K., Rockhill J., Rusthoven C., Shonka N., Swinnen L.J., Weiss S., Wen P.Y., Willmarth N.E., Bergman M.A., Darlow S. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. J Natl Compr Canc Netw. 2023; 21(1): 12–20. doi: 10.6004/jnccn.2023.0002.</mixed-citation><mixed-citation xml:lang="en">Horbinski C., Nabors L.B., Portnow J., Baehring J., Bhatia A., Bloch O., Brem S., Butowski N., Cannon D.M., Chao S., Chheda M.G., Fabiano A.J., Forsyth P., Gigilio P., Hattangadi-Gluth J., Holdhoff M., Junck L., Kaley T., Merrell R., Mrugala M.M., Nagpal S., Nedzi L.A., Nevel K., Nghiemphu P.L., Parney I., Patel T.R., Peters K., Puduvalli V.K., Rockhill J., Rusthoven C., Shonka N., Swinnen L.J., Weiss S., Wen P.Y., Willmarth N.E., Bergman M.A., Darlow S. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. J Natl Compr Canc Netw. 2023; 21(1): 12–20. doi: 10.6004/jnccn.2023.0002.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Rogers L., Zhang P., Vogelbaum M.A., Perry A., Ashby L.S., Modi J.M., Alleman A.M., Galvin J., Brachman D., Jenrette J.M., De Groot J., Bovi J.A., Werner-Wasik M., Knisely J.P.S., Mehta M.P. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2018; 129(1): 35–47. doi: 10.3171/2016.11.JNS161170. Epub 2017 Oct 6. Erratum in: J Neurosurg. 2018; 129(6): 1650.</mixed-citation><mixed-citation xml:lang="en">Rogers L., Zhang P., Vogelbaum M.A., Perry A., Ashby L.S., Modi J.M., Alleman A.M., Galvin J., Brachman D., Jenrette J.M., De Groot J., Bovi J.A., Werner-Wasik M., Knisely J.P.S., Mehta M.P. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2018; 129(1): 35–47. doi: 10.3171/2016.11.JNS161170. Epub 2017 Oct 6. Erratum in: J Neurosurg. 2018; 129(6): 1650.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Weber D.C., Ares C., Villa S., Peerdeman S.M., Renard L., Baumert B.G., Lucas A., Veninga T., Pica A., Jefferies S., Ricardi U., Miralbell R., Stelmes J.J., Liu Y., Collette L., Collette S. Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042). Radiother Oncol. 2018; 128(2): 260–5. doi: 10.1016/j.radonc.2018.06.018.</mixed-citation><mixed-citation xml:lang="en">Weber D.C., Ares C., Villa S., Peerdeman S.M., Renard L., Baumert B.G., Lucas A., Veninga T., Pica A., Jefferies S., Ricardi U., Miralbell R., Stelmes J.J., Liu Y., Collette L., Collette S. Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042). Radiother Oncol. 2018; 128(2): 260–5. doi: 10.1016/j.radonc.2018.06.018.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Chen W.C., Perlow H.K., Choudhury A., Nguyen M.P., Mirchia K., Youngblood M.W., Lucas C.G., Palmer J.D., Magill S.T., Raleigh D.R. Radiotherapy for meningiomas. J Neurooncol. 2022; 160(2): 505–15. doi: 10.1007/s11060-022-04171-9.</mixed-citation><mixed-citation xml:lang="en">Chen W.C., Perlow H.K., Choudhury A., Nguyen M.P., Mirchia K., Youngblood M.W., Lucas C.G., Palmer J.D., Magill S.T., Raleigh D.R. Radiotherapy for meningiomas. J Neurooncol. 2022; 160(2): 505–15. doi: 10.1007/s11060-022-04171-9.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Agnihotri S., Suppiah S., Tonge P.D., Jalali S., Danesh A., Bruce J.P., Mamatjan Y., Klironomos G., Gonen L., Au K., Mansouri S., Karimi S., Sahm F., von Deimling A., Taylor M.D., Laperriere N.J., Pugh T.J., Aldape K.D., Zadeh G. Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. Nat Commun. 2017; 8(1): 186. doi: 10.1038/s41467-017-00174-7.</mixed-citation><mixed-citation xml:lang="en">Agnihotri S., Suppiah S., Tonge P.D., Jalali S., Danesh A., Bruce J.P., Mamatjan Y., Klironomos G., Gonen L., Au K., Mansouri S., Karimi S., Sahm F., von Deimling A., Taylor M.D., Laperriere N.J., Pugh T.J., Aldape K.D., Zadeh G. Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. Nat Commun. 2017; 8(1): 186. doi: 10.1038/s41467-017-00174-7.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Gillespie C.S., Islim A.I., Taweel B.A., Millward C.P., Kumar S., Rathi N., Mehta S., Haylock B.J., Thorp N., Gilkes C.E., Lawson D.D.A., Mills S.J., Chavredakis E., Farah J.O., Brodbelt A.R., Jenkinson M.D. The growth rate and clinical outcomes of radiation induced meningioma undergoing treatment or active monitoring. J Neurooncol. 2021; 153(2): 239–49. doi: 10.1007/s11060-021-03761-3.</mixed-citation><mixed-citation xml:lang="en">Gillespie C.S., Islim A.I., Taweel B.A., Millward C.P., Kumar S., Rathi N., Mehta S., Haylock B.J., Thorp N., Gilkes C.E., Lawson D.D.A., Mills S.J., Chavredakis E., Farah J.O., Brodbelt A.R., Jenkinson M.D. The growth rate and clinical outcomes of radiation induced meningioma undergoing treatment or active monitoring. J Neurooncol. 2021; 153(2): 239–49. doi: 10.1007/s11060-021-03761-3.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Horbinski C., Nabors L.B., Portnow J., Baehring J., Bhatia A., Bloch O., Brem S., Butowski N., Cannon D.M., Chao S., Chheda M.G., Fabiano A.J., Forsyth P., Gigilio P., Hattangadi-Gluth J., Holdhoff M., Junck L., Kaley T., Merrell R., Mrugala M.M., Nagpal S., Nedzi L.A., Nevel K., Nghiemphu P.L., Parney I., Patel T.R., Peters K., Puduvalli V.K., Rockhill J., Rusthoven C., Shonka N., Swinnen L.J., Weiss S., Wen P.Y., Willmarth N.E., Bergman M.A., Darlow S. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. 2023; 21(1). doi: 10.6004/jnccn.2023.0002.</mixed-citation><mixed-citation xml:lang="en">Horbinski C., Nabors L.B., Portnow J., Baehring J., Bhatia A., Bloch O., Brem S., Butowski N., Cannon D.M., Chao S., Chheda M.G., Fabiano A.J., Forsyth P., Gigilio P., Hattangadi-Gluth J., Holdhoff M., Junck L., Kaley T., Merrell R., Mrugala M.M., Nagpal S., Nedzi L.A., Nevel K., Nghiemphu P.L., Parney I., Patel T.R., Peters K., Puduvalli V.K., Rockhill J., Rusthoven C., Shonka N., Swinnen L.J., Weiss S., Wen P.Y., Willmarth N.E., Bergman M.A., Darlow S. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. 2023; 21(1). doi: 10.6004/jnccn.2023.0002.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Dubel G.J., Ahn S.H., Soares G.M. Contemporary endovascular embolotherapy of meningioma. Semin Intervent Radiol. 2013; 30(3): 263–77. doi: 10.1055/s-0033-1353479.</mixed-citation><mixed-citation xml:lang="en">Dubel G.J., Ahn S.H., Soares G.M. Contemporary endovascular embolotherapy of meningioma. Semin Intervent Radiol. 2013; 30(3): 263–77. doi: 10.1055/s-0033-1353479.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Engelhard H.H. Progress in the diagnosis and treatment of patients with meningiomas. Part I: diagnostic imaging, preoperative embolization. Surg Neurol. 2001; 55(2): 89–101. doi: 10.1016/s0090- 3019(01)00349-4.</mixed-citation><mixed-citation xml:lang="en">Engelhard H.H. Progress in the diagnosis and treatment of patients with meningiomas. Part I: diagnostic imaging, preoperative embolization. Surg Neurol. 2001; 55(2): 89–101. doi: 10.1016/s0090- 3019(01)00349-4.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Dowd C.F., Halbach V.V., Higashida R.T. Meningiomas: the role of preoperative angiography and embolization. Neurosurg Focus. 2003; 15(1). doi:10.3171/foc.2003.15.1.10.</mixed-citation><mixed-citation xml:lang="en">Dowd C.F., Halbach V.V., Higashida R.T. Meningiomas: the role of preoperative angiography and embolization. Neurosurg Focus. 2003; 15(1). doi:10.3171/foc.2003.15.1.10.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Bendszus M., Martin-Schrader I., Schlake H.P., Solymosi L. Embolisation of intracranial meningiomas without subsequent surgery. Neuroradiology. 2003; 45(7): 451–5. doi: 10.1007/s00234-003-1005-1.</mixed-citation><mixed-citation xml:lang="en">Bendszus M., Martin-Schrader I., Schlake H.P., Solymosi L. Embolisation of intracranial meningiomas without subsequent surgery. Neuroradiology. 2003; 45(7): 451–5. doi: 10.1007/s00234-003-1005-1.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Koike T., Sasaki O., Tanaka R., Arai H. Long-term results in a case of meningioma treated by embolization alone – case report. Neurol Med Chir (Tokyo). 1990; 30(3): 173–7. doi: 10.2176/nmc.30.173.</mixed-citation><mixed-citation xml:lang="en">Koike T., Sasaki O., Tanaka R., Arai H. Long-term results in a case of meningioma treated by embolization alone – case report. Neurol Med Chir (Tokyo). 1990; 30(3): 173–7. doi: 10.2176/nmc.30.173.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Wakhloo A.K., Juengling F.D., Van Velthoven V., Schumacher M., Hennig J., Schwechheimer K. Extended preoperative polyvinyl alcohol microembolization of intracranial meningiomas: assessment of two embolization techniques. Am J Neuroradiol. 1993; 14(3): 571–82.</mixed-citation><mixed-citation xml:lang="en">Wakhloo A.K., Juengling F.D., Van Velthoven V., Schumacher M., Hennig J., Schwechheimer K. Extended preoperative polyvinyl alcohol microembolization of intracranial meningiomas: assessment of two embolization techniques. Am J Neuroradiol. 1993; 14(3): 571–82.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Barresi V., Branca G., Granata F., Alafaci C., Caffo M., Tuccari G. Embolized meningiomas: risk of overgrading and neo-angiogenesis. J Neurooncol. 2013; 113(2): 207–19. doi: 10.1007/s11060-013-1117-3.</mixed-citation><mixed-citation xml:lang="en">Barresi V., Branca G., Granata F., Alafaci C., Caffo M., Tuccari G. Embolized meningiomas: risk of overgrading and neo-angiogenesis. J Neurooncol. 2013; 113(2): 207–19. doi: 10.1007/s11060-013-1117-3.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Perry A., Chicoine M.R., Filiput E., Miller J.P., Cross D.T. Clinicopathologic assessment and grading of embolized meningiomas: a correlative study of 64 patients. Cancer. 2001; 92(3): 701–11. doi: 10.1002/1097-0142(20010801)92:33.0.co;2-7.</mixed-citation><mixed-citation xml:lang="en">Perry A., Chicoine M.R., Filiput E., Miller J.P., Cross D.T. Clinicopathologic assessment and grading of embolized meningiomas: a correlative study of 64 patients. Cancer. 2001; 92(3): 701–11. doi: 10.1002/1097-0142(20010801)92:33.0.co;2-7.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Jensen R.L., Soleau S., Bhayani M.K., Christiansen D. Expression of hypoxia inducible factor-1 alpha and correlation with preoperative embolization of meningiomas. J Neurosurg. 2002; 97(3): 658–67. doi: 10.3171/jns.2002.97.3.0658.</mixed-citation><mixed-citation xml:lang="en">Jensen R.L., Soleau S., Bhayani M.K., Christiansen D. Expression of hypoxia inducible factor-1 alpha and correlation with preoperative embolization of meningiomas. J Neurosurg. 2002; 97(3): 658–67. doi: 10.3171/jns.2002.97.3.0658.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
